A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides

Completed · Phase 2 · Has a placebo group

Conditions studied: Dyslipidemia

In brief

This Phase 2 proof-of-concept study will assess the lipid regulating efficacy and safety of ETC-1002 in subjects with hypercholesterolemia and either normal or elevated triglycerides.

Key facts

Study ID

NCT01262638

Run by

Esperion Therapeutics, Inc.

People needed

177

Starts

2010-12-01

Expected to finish

2011-08-23

Last updated by the study team

2021-03-17

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Chandler, Arizona, United States
• Study site — Greenbrae, California, United States
• Study site — Santa Rosa, California, United States
• Study site — Jacksonville, Florida, United States
• Study site — Chicago, Illinois, United States
• Study site — Iowa City, Iowa, United States
• Study site — Louisville, Kentucky, United States
• Study site — Kalamazoo, Michigan, United States
• Study site — Raleigh, North Carolina, United States
• Study site — Houston, Texas, United States
• Study site — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.